Christensen R D, Brown M S, Hall D C, Lassiter H A, Hill H R
Divisions of Human Development and Aging, University of Utah School of Medicine, Salt Lake City 84132.
J Pediatr. 1991 Apr;118(4 Pt 1):606-14. doi: 10.1016/s0022-3476(05)83389-x.
This study was designed to test the hypothesis that administration of immune globulin to human neonates with early-onset bacterial sepsis would (1) facilitate neutrophil egress from the marrow, (2) improve serum opsonic capacity, and (3) facilitate recovery from the infectious illness. Twenty-two newborn infants with clinical signs of early-onset sepsis were given an intravenous infusion of either 750 mg of immune globulin (IVIG) per kilogram of body weight or the same volume of a vehicle control (albumin). All 22 infants survived, but significant hematologic, immunologic, and respiratory differences were observed after the IVIG and not after the control infusion. Eleven of the patients had neutropenia; 24 hours after the infusions, the neutropenia had resolved in all six IVIG recipients but persisted in all five control recipients (p less than 0.001). Ten patients had I/T neutrophil ratios (a measure of immature neutrophils to total neutrophils on the leukocyte differential count) of less than 0.2. One hour after completion of the infusions, all five IVIG recipients had elevated I/T ratios (mean +/- SEM:0.10 +/- 0.05 before vs 0.43 +/- 0.03 after infusion; p less than 0.001), suggesting a prompt release of neutrophils from the marrow neutrophil storage pool into the circulation; no increase in the I/T ratio was observed in the control recipients. Six hours after the IVIG infusions, the ratio of arterial oxygen tension to fraction of inspired oxygen increased; no increase was observed after control infusions. Serum concentrations of IgG, IgG1, IgG2, IgG3, IgG4, and total hemolytic complement and the capacity of serum to support opsonophagocytosis of type II and type III group B streptococci increased markedly in the IVIG recipients but not in the control subjects. We conclude that administration of 750 mg IVIG per kilogram to neonates with clinical signs of early-onset sepsis was associated with immunologic, hematologic, and physiologic improvement.
给患有早发性细菌性败血症的人类新生儿注射免疫球蛋白会(1)促进中性粒细胞从骨髓中逸出,(2)提高血清调理素能力,以及(3)促进从感染性疾病中恢复。22名有早发性败血症临床体征的新生儿被静脉输注每千克体重750毫克免疫球蛋白(IVIG)或相同体积的载体对照(白蛋白)。所有22名婴儿均存活,但在输注IVIG后观察到显著的血液学、免疫学和呼吸方面的差异,而在对照输注后未观察到这些差异。11名患者有中性粒细胞减少症;输注后24小时,所有6名接受IVIG的患者中性粒细胞减少症均已缓解,但所有5名接受对照输注的患者中性粒细胞减少症仍持续存在(p<0.001)。10名患者的未成熟中性粒细胞与总中性粒细胞比值(白细胞分类计数中未成熟中性粒细胞与总中性粒细胞的比值)小于0.2。输注完成1小时后,所有5名接受IVIG的患者未成熟中性粒细胞与总中性粒细胞比值升高(平均值±标准误:输注前为0.10±0.05,输注后为0.43±0.03;p<0.001),表明中性粒细胞迅速从骨髓中性粒细胞储存池释放到循环中;对照输注的患者未观察到未成熟中性粒细胞与总中性粒细胞比值增加。IVIG输注6小时后,动脉血氧分压与吸入氧分数的比值增加;对照输注后未观察到增加。IVIG接受者血清中IgG、IgG1、IgG2、IgG3、IgG4和总溶血补体的浓度以及血清支持II型和III型B组链球菌调理吞噬作用的能力显著增加,而对照受试者未增加。我们得出结论,给有早发性败血症临床体征的新生儿每千克体重注射750毫克IVIG与免疫、血液学和生理改善相关。